Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Double-blind Randomized Placebo-controlled Study of Olpasiran in Patients With Elevated Lipoprotein(a)
jRCT2031200367Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2020
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of olpasiran in atherosclerotic disease and lipoprotein(a) hyperlipoproteinemia (Lp(a)) (5 arms), sponsored by Amgen. Primary endpoint: Percentage Change From Baseline in Lipoprotein(a) at Week 36. Started Jul 2020; status: completed.
02
Drugs
olpasiran
03
Conditions
atherosclerotic diseaselipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on jRCT2031200367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200367.